Cover of the China Pharmaceutical Innovation Archive 2025

The 2025 edition · 52 pages

Annual Reference · 2025 Edition

China Pharmaceutical Innovation Archive

The definitive annual reference on China’s pharmaceutical innovation landscape — the regulatory reforms, insurance negotiations and licensing deals that reshaped the world’s second-largest drug market.

52 pages 8 hotspot features 4 research sections Fully sourced

PDF $599 · Hardcopy $599 · Published by Fineline BioInsights

2024 · The Year in Numbers

A market that moved from follower to source.

42
Global-new drugs approved by NMPA
Category 1 products not yet approved anywhere else in the world. CPIA 2025, §3.1
$6.2B
Total licensing deal value — a record high
Nearly $6.2B across 200+ deals; out-licensing ≈ 90% of value. CPIA 2025, §6
100+
Novel drug approvals in a single year — first time
107 new molecules approved in 2024, up from 22 in 2015. CPIA 2025, Figure 3
⅓
Of MNC-introduced products now originate from China
By 2024, per authoritative statistics cited in the CPIA 2025 preface

Every figure above is traced to a primary regulatory source inside the Archive — with the underlying tables reproduced in full.

02 — Inside the Archive

Not commentary. Evidence.

Actual pages from the 2025 edition. The Archive reproduces the approval records, negotiation outcomes and deal tables behind every conclusion.

Figure 3 from CPIA 2025: stacked bar chart of new molecules and Category 1 drugs approved in China, 2015 to 2024, rising from 22 to 107
Figure 3 · New molecules & Category 1 drugs, 2015–2024p.19
Figure 6 from CPIA 2025: bar chart showing average years from new drug approval to NRDL entry falling from 8.1 in 2016 to 1.3 in 2024
Figure 6 · Approval-to-reimbursement lag, 2016–2024p.32

Structure of the 2025 edition

  1. 012024 Yearly Hotspots ReviewEight features: record approvals, NRDL negotiations, the 10th VBP round, outbound licensing, patent term extension, the Class C drug list.
  2. 02China’s Pharmaceutical Development HistoryThe reform decades behind today’s market — from the 1979 rules to the 2015 overhaul and its aftermath.
  3. 03Enterprise Strategic TransformationHow multinationals and domestic players are repositioning for a China that now exports innovation.
  4. 04Outlook for 2025Policy direction, payment reform and the cross-border deal pipeline to watch.
52 pages8 hotspot features4 research sectionsPDF + Hardcopy

03 — Methodology

Research you can trace.

3.1

Primary regulatory sources

NMPA approval records, NHSA negotiation outcomes and official policy documents — read in the original, not through secondhand summaries.

3.2

Official approval data

Every approval, designation and reimbursement decision in the Archive is drawn from the regulator’s own published data.

3.3

Verified transaction records

Licensing deals are checked against company disclosures and verified records. Where a figure is provisional or estimated, the report says so.

“We do not publish speculation.” Fineline BioInsights · Research Methodology

04 — Editorial Team

The people behind the Archive.

Karia Olsen

Managing Editor

Pharmaceutical industry analyst with 15 years of experience. Master’s degree in Pharmacy from Fudan University; a decade at a multinational pharmaceutical consultancy.

Emily Zhang

Design Lead

Responsible for the Archive’s data visualisation and publication design — every chart rebuilt for clarity and traceability.

Leona Zeng

Production Manager

Oversees fact-checking, source verification and the production of each edition in PDF and hardcopy.

Fineline BioInsights is the pharmaceutical research and publishing division of Fineline Information & Technology. All reports are company publications; copyright belongs to Fineline Information & Technology.

05 — Coverage Areas

Four lenses on one market.

  1. 01

    Regulatory Affairs

    NMPA approval trends, priority review, breakthrough therapy designations and patent term extensions.

  2. 02

    Market Access

    NRDL negotiations, volume-based procurement and the pricing dynamics shaping patient access.

  3. 03

    BD & Licensing

    License-out transactions, NewCo structures and the cross-border deals driving China’s global rise.

  4. 04

    Policy & Trade

    Industrial policy, U.S.–China trade developments and their impact on the global drug market.

The 2025 Edition

The year China’s drug industry changed — documented.

One annual volume. Every approval, every negotiation, every deal that mattered — traced to its source.

PDF $599 · Hardcopy $599 · Institutional enquiries welcome